A Real-World Study of Guselkumab in Ulcerative Colitis and Crohn's Disease in Saudi Arabia

The main purpose of this study is to evaluate treatment persistence of guselkumab (that is how long a person keeps taking their prescribed medicine or continues with their treatment plan without stopping) in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.

NCT Number	NCT07541261
Lead Sponsor	Janssen Research & Development, LLC
Conditions	Colitis, Ulcerative, Crohn Disease
Enrollment	100 participants
Start Date	2026-05-12
Primary Completion	2029-01-02 (estimated)
Study Completion	2029-01-29 (estimated)
Updated on ClinicalTrials.gov	2026-07-02